Psychological Resilience in Frontline Health Care Workers During the Acute Phase of the COVID-19 Pandemic in New York City

TY - JOUR

T1 - Psychological Resilience in Frontline Health Care Workers During the Acute Phase of the COVID-19 Pandemic in New York City

AU - Pietrzak, Robert H.

AU - Feingold, Jordyn H.

AU - Feder, Adriana

AU - Charney, Dennis S.

AU - Peccoralo, Lauren

AU - Southwick, Steven M.

AU - Ripp, Jonathan

N1 - Funding Information: This study was supported by internal funding devoted to COVID-19-related projects from the Icahn School of Medicine at Mount Sinai. Preparation of this report was supported in part by the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder (Dr Pietrzak). The authors thank all of the participants at the Mount Sinai Hospital who participated in this study. They also acknowledge the COVID-19 Psychological Impact Study Team for their contributions to this project: Chi C. Chan, PhD; Carly A. Kaplan, BS; Halley Kaye-Kauderer, BA; Jaclyn Verity, MPH; Larissa Burka, RN; Alicia Hurtado, MD; and James W. Murrough, MD, PhD. Funding Information: interpretation of data: All authors. Drafting of the manuscript: Pietrzak, Feder, Southwick, Ripp. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Pietrzak. Administrative, technical, or material support: Feingold, Ripp, Peccoralo, Charney Supervision: Southwick, Ripp. Potential conflicts of interest: Dr Feder is named co-inventor on an issued patent in the US, and several issued patents outside the US, filed by the Icahn School of Medicine at Mount Sinai (ISMMS) for the use of ketamine as a therapy for PTSD. This intellectual property has not been licensed. Dr Charney is named as co-inventor on patents filed by the Icahn School of Medicine at Mount Sinai (ISMMS) relating to the treatment for treatment-resistant depression, suicidal ideation, and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), Dr Charney is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, Dr Charney, will be entitled to additional payments, beyond those already received, under the license agreement. Dr Charney is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, Dr Charney has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. Dr Charney is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. Dr Charney is a named co-inventor on a patent application in the US and several issued patents outside the US filed by the ISMMS related to the use of ketamine for the treatment of posttraumatic stress disorder. This intellectual property has not been licensed. The other authors have no disclosures to report. Funding/support: This study was supported by internal funding devoted to COVID-19–related projects from the Icahn School of Medicine at Mount Sinai. Preparation of this report was supported in part by the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder (Dr Pietrzak). Role of the sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Acknowledgments: The authors thank all of the participants at the Mount Sinai Hospital who participated in this study. They also acknowledge the COVID-19 Psychological Impact Study Team for their contributions to this Verity, MPH; Larissa Burka, RN; Alicia Hurtado, MD; and James W. Murrough, 3. Bryant RA. The current evidence for acute stress disorder. Curr Psychiatry MD, PhD. Rep. 2018;20(12):111.PubMed CrossRef Supplementarymaterial:Available at PSYCHIATRIST.COM. 4. Joyce S, Shand F, Tighe J, et al. Road to resilience: a systematic review and meta-analysis of resilience training programmes and interventions. BMJ Open. 2018;8(6):e017858.PubMed CrossRef 5. Maunder RG, Lancee WJ, Mae R, et al. Computer-assisted resilience training to prepare healthcare workers for pandemic influenza: a randomized trial of the optimal dose of training. BMC Health Serv Res. 2010;10(1):72.PubMed CrossRef 6. West CP, Dyrbye LN, Erwin PJ, et al. Interventions to prevent and reduce physician burnout: a systematic review and meta-analysis. Lancet. 2016;388(10057):2272–2281.PubMed CrossRef

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85114259422&partnerID=8YFLogxK

U2 - 10.4088/JCP.20L13749

DO - 10.4088/JCP.20L13749

M3 - Article

AN - SCOPUS:85114259422

SN - 0160-6689

VL - 82

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

IS - 1

M1 - 20l13749

ER -